Cancer Causes & Control

, Volume 9, Issue 4, pp 425–432 | Cite as

Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)

  • Abraham M.Y. Nomura
  • Grant N. Stemmermann
  • James Lee
  • Laurence N. Kolonel
  • Tai C. Chen
  • Adrian Turner
  • Michael F. Holick

Abstract

Objectives: Because several serum studies of vitamin D metabolites have produced equivocal results on their relation to prostate cancer risk, the purpose of this study is to evaluate this association further.

Methods: A nested case-control study in a cohort of 3,737 Japanese-American men examined from 1967 to 1970 was conducted in Hawaii (United States). At the time of examination, a single blood specimen was obtained, and the serum was frozen. After a surveillance period of over 23 years, 136 tissue-confirmed incident cases of prostate cancer were identified. Their stored sera and those of 136 matched controls were measured for the following: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, calcium, phosphorus, and parathyroid hormone.

Results: There were no notable differences between cases and controls in their median serum levels of the five laboratory measurements. Odds ratios (OR) for prostate cancer, based on the quartiles of serum levels in controls, were also determined. The ORs for the highest quartiles relative to the lowest were 0.8 (95 percent confidence interval [CI] = 0.4-1.8) for 25-hydroxyvitamin D and 1.0 (CI = 0.5-2.1) for 1,25-dihydroxyvitamin D.

Conclusion: It is possible that the lack of sufficient numbers of study subjects with low vitamin D levels affected the results. Nonetheless, the findings suggest that there is a lack of a strong association between vitamin D and prostate cancer.

Prostate cancer United States vitamin D 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis) Anticancer Res 1990; 10: 1307–11.Google Scholar
  2. 2.
    Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomark Prev 1993; 2: 467–72.Google Scholar
  3. 3.
    Braun MM, Helzsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995; 6: 235–9.Google Scholar
  4. 4.
    Corder EH, Friedman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomark Prev 1995; 4: 655–9.Google Scholar
  5. 5.
    Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomark Prev 1996; 5: 121–6.Google Scholar
  6. 6.
    Miller GJ, Stapleton GE, Ferrara JA, et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1,25-Dihydroxyvitamin D3. Cancer Res 1992; 52: 515–20.Google Scholar
  7. 7.
    Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1,25-Dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993; 132: 1952–60.Google Scholar
  8. 8.
    Peehl DM, Skowronski RJ, Leung GK, Wont ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25 Dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994; 54: 805–10.Google Scholar
  9. 9.
    Skowronski RJ, Peehl DM, Feldman D. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136: 20–6.Google Scholar
  10. 10.
    Schwartz GG, Oeler TA, Uskokovic MR, Bahnson RR. Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. Anticancer Res 1994; 14: 1077–81.Google Scholar
  11. 11.
    Stamp TCB, Round JM. Seasonal changes in human plasma levels of 25-hydroxyvitamin D. Nature 1974; 247: 563–5.Google Scholar
  12. 12.
    Tjellesen L, Christiansen C. Vitamin D metabolites in normal subjects during one year. A longitudinal study. Scand J Clin Lab Invest 1983; 43: 5–9.Google Scholar
  13. 13.
    Patale AA, Halloran BF, Murphy MM, Morris RC. Oral intake of phosphorus can determine serum concentrations of 1,15-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986; 77: 7–12.Google Scholar
  14. 14.
    Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N Engl J Med 1989; 320: 980–91.Google Scholar
  15. 15.
    Chen TC, Turner AK, Holick MF. Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J Nutr Biochem 1990; 1: 315–9.Google Scholar
  16. 16.
    Chen TC, Turner AK, Holick MF. A method for the determination of the circulating concentration of 1,25-dihydroxyvitamin D. J Nutr Biochem 1990; 1: 320–7.Google Scholar
  17. 17.
    Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunometric assay of parathyrin and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364–7.Google Scholar
  18. 18.
    Armitage P, Berry G. Statistical Methods in Medical Research. Oxford, UK: Blackwell Scientific Publications, 1987: 120–3.Google Scholar
  19. 19.
    Hosmer DW, Lemeshow C. Applied Logistic Regression. New York, NY (USA): John Wiley & Sons, 1989: 190–7.Google Scholar
  20. 20.
    Tukey J. Exploratory Data Analysis. New York, NY (USA): Addison-Wesley, 1977: 100.Google Scholar
  21. 21.
    Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108–10.Google Scholar
  22. 22.
    Ingles SA, Ross RK, Yu MC, et al. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 1997; 89: 166–70.Google Scholar
  23. 23.
    Feldman D. Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst 1997; 89: 109–11.Google Scholar

Copyright information

© Kluwer Academic Publishers 1998

Authors and Affiliations

  • Abraham M.Y. Nomura
    • 1
  • Grant N. Stemmermann
    • 2
  • James Lee
    • 3
  • Laurence N. Kolonel
    • 3
  • Tai C. Chen
    • 4
  • Adrian Turner
  • Michael F. Holick
    • 4
  1. 1.Kuakini Medical CenterJapan-Hawaii Cancer StudyHonoluluUSA
  2. 2.Department of PathologyUniversity of Cincinnati Medical CenterCincinnatiUSA
  3. 3.Epidemiology Program, Cancer Research CenterUniversity of HawaiiHonolulu
  4. 4.General Clinical Research Center, Department of MedicineBoston University School of MedicineBostonUSA

Personalised recommendations